Verseon Corporation Announcement of 2019 Annual General Meeting (4387Q)
18 Ottobre 2019 - 04:38PM
UK Regulatory
TIDMVERS
RNS Number : 4387Q
Verseon Corporation
18 October 2019
Press release October 18, 2019
Verseon Corporation
("Verseon" or the "Company")
Announcement of 2019 Annual General Meeting
FREMONT, Calif.-Verseon Corporation (AIM:VERS), the
clinical-stage pharmaceutical company developing products and
technologies to advance global health, today announces that its
2019 Annual General Meeting ("AGM") will be held on October 28,
2019, at 9 a.m. local time at the Critosphere Cowork Space, 7100
Stevenson Blvd. Fremont, CA 94538, USA.
At the AGM, the Company will seek shareholder approval for the
following matters:
(a) Re-election of non-executive Class I Directors Dr. Thomas
Hecht and Dr. Sangtae Kim
(b) The sale of the Company's headquarters
The Company seeks shareholder approval or ratification for the
sale of its research, development, and operations facility located
at 47071 Bayside Parkway, Fremont, California (the "Property") to
provide working capital for the Company. Further details of the
sale will be announced via RNS without delay once available in
accordance with AIM Rules ahead of the AGM. If this is not
possible, a separate notice of general meeting will be sent to
shareholders to approve the sale of the Property and this building
sale resolution will be withdrawn from the AGM.
(c) Such other business as may properly come before shareholders present, in person or by proxy
Copies of the 2019 AGM Proxy Information Statement are available
to view and download between October 18 and October 28, 2019 from
the Company's website at
http://www.verseon.com/investor-notices/agm2019.
- Ends -
For further information, please contact
Verseon Corporation www.verseon.com
Sebastian Wykeham / Tina Schlafly +1 (510) 225 9000
Arden Partners (NOMAD and Joint Broker)
Ruari McGirr / Ciaran Walsh / Dan Gee-Summons
(Corporate Finance) / Fraser Marshall +44 (0) 20 7614
(Equity Sales) 5900
Cantor Fitzgerald Europe (Joint Broker)
+44 (0) 20 7894
Phil Davies 7000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737 821
Simon Vane Percy 890
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAFFMFLAFUSEDS
(END) Dow Jones Newswires
October 18, 2019 10:38 ET (14:38 GMT)
Grafico Azioni Verseon (LSE:VERS)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Verseon (LSE:VERS)
Storico
Da Mar 2023 a Mar 2024